InnoCan Pharma Corporation (INNO.CN)

0.2200 0.0000 (0.00%) As of 11:18AM EDT. Market open.

InnoCan Pharma Corporation

1015, 926 – 5 Avenue SW
Calgary, AB T2P 0N7
Canada
403-777-1519
https://innocanpharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Ron Mayron	Executive Chairman	182.91k	N/A	1963
Ms. Iris Bincovich	CEO & Director	453.23k	N/A	1970
Mr. Nelson Harvey Halpern F.C.A., FCPA	Chief Financial Officer	86.07k	N/A	1959
Mr. Roni Kamhi	COO & CEO of BI Sky Global and Director	309.33k	N/A	1973
Mr. Eyal Flom L.L.M., M.B.A.	Director & Company Secretary	N/A	N/A	1967
Mr. Yoram Drucker	Founder & Executive VP of Business Development	232.67k	N/A	1965

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management. The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products. In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.

Corporate Governance

InnoCan Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.